Communiqués Sleep Cycle AB

Actions

SLEEP

SE0015961404

Logiciels

Temps Différé Nasdaq Stockholm 18:00:00 14/09/2026			Varia. 5j.	Varia. 1 janv.
22,15 ^SEK	+0,68%		+2,07%	-13,65%

11/09	Sleep Cycle accélère le lancement européen de son dispositif de détection du risque d'apnée du sommeil en tant que dispositif médical de classe I	CI
11/09	Sleep Cycle avance le lancement européen de sa solution contre l'apnée du sommeil	FW

Communiqués

14/09	Sleep Cycle: Sleep apnea launches in Europe first, US pathway paused	AQ
11/09	Sleep Cycle Accelerates European Launch of Sleep Apnea Risk Detection While Preserving Pathway to US Regulatory Clearance	AQ
04/09	Sleep Cycle's sleep analysis moves inside the product as partner Moera launches temperature-regulating mattress toppers	AQ
03/09	AI Sleep Data Could Provide One-Week Early Warning of Flu and COVID-19 Activity	AQ
27/08	Sleep Cycle: Change of CEO, no total surprise given new main owner and board	AQ
27/08	Sleep Cycle (Q2 Review):B2B momentum intact, MedTech delayed by enrollment, not engineering	AQ
27/08	Sleep Cycle appoints Mikael Kågebäck as acting CEO	AQ
26/08	Sleep Cycle Interim Report April - June 2026: A greater opportunity takes shape	PU
26/08	Sleep Cycle Interim Report April – June 2026: A greater opportunity takes shape	AQ
24/08	Sleep Cycle AB (publ) invites you to a presentation of the second quarter of 2026	AQ
05/08	Resolutions at Sleep Cycle’s Extraordinary General Meeting 2026	AQ
23/07	Sleep Cycle signs tech licensing agreement with Ant Group	AQ
20/07	Snark BidCo announces outcome in the extended acceptance period in the offer to Sleep Cycle shareholders	AQ
10/07	Notice of Extraordinary General Meeting in Sleep Cycle AB (publ)	AQ
03/07	Snark BidCo announces outcome and completes the offer to Sleep Cycle shareholders and thereby becomes owner of 78.2 percent of the shares	AQ
03/07	Sleep Cycle signs commercial SDK licensing agreement with Ultrahuman following successful pilot	AQ
22/05	The Board of Directors of Sleep Cycle unanimously recommends the shareholders not to accept the public cash offer by Altor	AQ
11/05	Sleep Cycle: Withdrawal of fair value range following Altor bid	AQ
11/05	The Board of Directors evaluates the offer from Altor	AQ
30/04	Sleep Cycle: B2B revenue continues to impress – Q1 review	AQ
29/04	Sleep Cycle: Strong revenue from new sources – Q1 initial take	AQ
29/04	Sleep Cycle Interim Report January – March 2026: Strategic expansion into new growth areas	AQ
28/04	Sleep Cycle AB (publ) invites you to a presentation of the first quarter of 2026	AQ
17/04	Sleep Cycle: Initiative to accelerate growth not discounted in share price	AQ
13/04	Resolutions at Sleep Cycle’s Annual General Meeting 2026	AQ